Clinical Edge Journal Scan

Surveillance endoscopy warranted in individuals at high risk for gastric cancer


 

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Recommended Reading

Stage II/III rectal cancer: Shift in treatment pattern and outcomes
MDedge Hematology and Oncology
BRAFV600E mCRC: No survival benefit of FOLFOXIRI+anti-VEGF over doublet+anti-VEGF
MDedge Hematology and Oncology
Distinctly different Acq-GAs profile with upfront anti-EGFR therapy and anti-EGFR-antibody therapy in later lines
MDedge Hematology and Oncology
Evidence supporting use of FIT at a threshold ≥10 μg/g in low-risk population
MDedge Hematology and Oncology
High red and processed meat intake tied with screen-detected colorectal lesions
MDedge Hematology and Oncology
Worse treatment response in KRASG12C-mutant metastatic CRC
MDedge Hematology and Oncology
Refractory mCRC: Trifluridine/tipiracil plus bevacizumab effective and safe in real world
MDedge Hematology and Oncology
Coadministration of H2RA may not reduce efficacy of capecitabine in early CRC
MDedge Hematology and Oncology
Elevated pretreatment plasma PD-L1 level indicates worse prognosis in mCRC
MDedge Hematology and Oncology
Intraperitoneal paclitaxel+XELOX: A promising treatment option for gastric cancer peritoneal metastases
MDedge Hematology and Oncology